Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

Recruiting

• Conditions: Interstitial Lung Disease
• Interventions: Other: ILD; Other: Healthy; Other: Pneumonia

• Registration Number: NCT03478826
• Lead Sponsor: Mayo Clinic

Brief Summary

To develop a repository of blood samples from patients with ILD to support future studies into the development of such biomarkers. Patients with pneumonia and healthy patients will also be recruited as a control group.

Detailed Description

The proposed biospecimen repository would be derived from patients diagnosed with ILD. This is to include 500 patients in the repository, with each patient contributing one blood sample. Patients with pneumonia and healthy patients will also be recruited as a control group.

Study Timeline

• Study First Submitted: 2018-03-23
• Study First Submitted QC: 2018-03-23
• Study First Posted: 2018-03-27
• Study Start: 2018-08-01
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-23
• Last Update Posted: 2025-04-27
• Primary Completion: 2028-01
• Study Completion: 2028-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 635

Inclusion Criteria

• Patients with a diagnosis of ILD or any fibrotic disease of the lung or a diagnosis of pneumonia
• Patients willing to provide written informed consent

Exclusion Criteria

• Unwillingness/unable to give blood samples

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
ILD	ILD	250 patients (male and females \>18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.
Healthy	Healthy	100 healthy participants as a control group.
Pneumonia	Pneumonia	25 patients with pneumonia as a control group.

Primary Outcome Measures

Name	Time	Method
Future Disease Management	1 visit	Reliable biomarkers to help guide treatment in ILD would be a major step forward in the management of this disease.

Trial Locations

Locations (1)

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States